America, Hershey, PA Australia, Melbourne, VIC Europe, Munich

Similar documents
Species Tumor Type Comment for in vivo work Lead Time for in vivo studies [weeks] MB-49-luc-2 Mouse urinary bladder carcinoma C57BL/6 2

Human cell line list Production of Exosome Standards - Cell Lysates

HansaBioMed Catalog 2014 for Exosome Research. X. Human Cell Lines...

SHN-1 Human Digestive Panel Test results

Supplementary Materials for

Evaluation of immunomodulatory agents in syngeneic models and immune cell phenotyping of humanized mouse models carrying patient-derived tumors

Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center

Sample validation data

MOLECULAR PHARMACOLOGY SUPPLEMENT

Supplementary Figure 1: Normal vs. Tumor expression of PIM kinases mrna across 17 tissue types

CLIC Sargent Eligibility Criteria

Macmillan Publications

Outcomes Report: Accountability Measures and Quality Improvements

Supplemental Methods LC-MS Assay for NAD Concentration

LavaCell. Fluorescent Cell Stain. (version A) Catalog No

2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill

incidence rate x 100,000/year

Truman Medical Center-Hospital Hill Cancer Registry 2014 Statistical Summary Incidence

Antitumor Activity of CUDC-305, a Novel Oral HSP90 Inhibitor, in Solid and Hematological Tumor Xenograft Models

Broad Spectrum, Targeted Approaches To Cancer Treatment

ACR TXIT TM EXAM OUTLINE

Oncology 101. Cancer Basics

Figure S1 Time-dependent down-modulation of HER3 by EZN No Treatment. EZN-3920, 2 μm. Time, h

Cancer prevalence. Chapter 7

H&HD ANTINEOPLASTIC DRUG CARD ASSEMBLY INSTRUCTIONS

Charles River Immunodeficient Models Xenograft Data Catalog

NOSCAN CLINICAL MANAGEMENT GUIDELINE (CMG) AND NOSCAN CHEMOTHERAPY REVIEW (NCR) STATUS DOCUMENT May Status (G / A / R) Status (G / A / R)

Tumour Structure and Nomenclature. Paul Edwards. Department of Pathology and Cancer Research UK Cambridge Institute, University of Cambridge

PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS

Thermo Scientific B R A H M S Biomarkers Tumor Marker Assays. Excellent precision. Confident cancer monitoring

The main credit of this work would go to the team of cancer epidemiology department without them this report would have never come into light.

Outcomes Report: Accountability Measures and Quality Improvements

Cancer in the organ donor

Annual Report. Cape Cod Hospital and Falmouth Hospital Regional Cancer Network Expert physicians. Quality hospitals. Superior care.

Epidemiology in Texas 2006 Annual Report. Cancer

Supplementary Online Content

Trial no. Status Phase Treatment Pre-conditioning Primary endpoints Secondary endpoints Diagnosis Sponsor

ANNUAL CANCER REGISTRY REPORT-2005

Supplementary Data Supplementary Table S1. IC 50 values of ipatasertib on cell viability in cell lines with

List of Available TMAs in the PRN

*

Cancer model Liver metastasis I

Purified Exosomes and Microvesicles

Heart Failure Transitions of Care SJMH - Ann Arbor

Juyoun Jin, D.V.M., Ph.D. Institute for Refractory Cancer Research, Samsung Medical Center

Burden of Cancer in California

Colorectal Cancer Screening

Cancer A Superficial Introduction

Maria Halasz CEO

Radiation Oncology Study Guide

Epidemiology of SV40-Associated Tumors

El contexto molecular de la sobreexpresión de PD-L1 Esther Conde Gallego, MD, PhD

Disease Source Species Name ATCC No. ATCC has approximately 1,100 tumor cell lines from a variety of species. Disease Source Species Name ATCC No.

Supplementary information table of content

THE BURDEN OF CANCER IN NEBRASKA: RECENT INCIDENCE AND MORTALITY DATA

Chapter 1 MAGNITUDE AND LEADING SITES OF CANCER

Genetic Alteration Panels

The mir-199a/brm/egr1 axis is a determinant of anchorage-independent growth in epithelial tumor cell lines

Inhibitors of Methionine Aminopeptidase-2 2 in the Treatment of Non-Hodgkin

National Cancer Drugs Fund List - Approved

Supplementary Material

Growth Surface References

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Knockdown of Malic Enzyme 2 Suppresses Lung Tumor Growth, Induces Differentiation and Impacts PI3K/AKT Signaling

Oncologic Applications of Interleukin-2 (Aldesleukin) When Used as Monotherapy. Original Policy Date

Cancer Association of South Africa (CANSA) Fact Sheet on the Top Ten Cancers per Population Group

Nuclear medicine in oncology. 1. Diagnosis 2. Therapy

155.2 Malignant neoplasm of liver not specified as primary or secondary. C22.9 Malignant neoplasm of liver, not specified as primary or secondary

Commissioning policies agreed by PCTs in Yorkshire and the Humber at Board meeting of YH SCG on December

Cancer in Ontario. 1 in 2. Ontarians will develop cancer in their lifetime. 1 in 4. Ontarians will die from cancer

CANCER IN TASMANIA INCIDENCE AND MORTALITY 1996

Tumor responses (patients responding/ patients treated)

Subject Cancers in Firefighters and Fire Investigators

National Cancer Statistics in Korea, 2014

TUMOR M ARKERS MARKERS

A gene expression bar code for microarray data

21st Century Adult Cancer Sourcebook: Adult Brain Tumors - Primary Malignant Tumors, Glioma, Astrocytoma, Meningioma, Oligodendroglioma, Ependymoma,

American Cancer Society Estimated Cancer Deaths by Sex and Age (years), 2013

Annual Report to the Nation on the Status of Cancer, , Featuring Survival Questions and Answers

Chapter 15: Non-Head and Neck Solid Tumors in Patients with Fanconi Anemia

Evaluation of Ancestry Information Markers (AIMs) from Previous ACOSOG/CALGB/NCCTG Trials

Neoplasms/Lymphoma/Leukemia

Supplementary Online Content

Liver cancer and normal cell lines

Cancer Program Report 2014

2008 Oncology Pharmacy Preparatory Review Course Learning Objectives

micrornas!as! Biomarkers! Landscape!

Impact and implications of Cancer Death Status Reporting Delay on Population- Based Relative Survival Analysis with Presumed-Alive Assumption

Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser

Icd 10 code for lung cancer with mets to bone

CANCER Uncontrolled Cell Division

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

BL-8040: BEST-IN-CLASS CXCR4 ANTAGONIST FOR TREATMENT OF ONCOLOGICAL MALIGNANCIES. Overview and Mechanism of Action Dr.

Oncology Centre Research Unit TUMOR REGISTRY

Cancer in Ireland with estimates for

Supplemental Data. Prolonged Rapamycin Treatment Inhibits mtorc2 Assembly and Akt/PKB. Supplemental Experimental Procedures

WLH Tumor Frequencies between cohort enrollment and 31-Dec Below the Women Lifestyle and Health tumor frequencies are tabulated according to:

Tissue Core Tissue Microarray Inventory List

Cancer Prevention & Control in Adolescent & Young Adult Survivors

Tumours in the donor: what is the risk?

Transcription:

America, Hershey, PA Australia, Melbourne, VIC Europe, Munich info@vivopharm.com www.vivopharm.com Bladder MB-9-luc 2 Mouse urinary bladder carcinoma yes yes yes C57BL/6 2 Bone UMR-106 Rat osteosarcoma no yes Brain A172 Glioblastoma no yes C6 Rat glial cell; gliaoma ; fibroblast no no DAOY desmoplastic cerebellar medulloblastoma yes yes GI-LI-N Neuroblastoma no yes IMR-32 human Neuroblastoma no yes LAN-5 Neuroblastoma no yes SNB-19 glioblastoma no yes U87MG glioblastoma; astrocytoma yes yes yes +/- luc Breast T1 Mouse breast carcinoma yes yes yes, also as metastasis model +/- luc, lung liver mets 2 BT-7 breast carcinoma yes yes yes Estrogen dependent, hormone pellets HER2 pos 2- EMT6 Mouse breast carcinoma yes no yes, also as metastasis model lung mets 2 HC 11 Mouse not tumorigenic yes HC 11-NeuT Mouse yes yes HCC195 breast carcinoma yes no yes slow growing, C.B-17 SCID HER2 pos 6 Hs 578Bst myoepithel, fibroblast not tumorigenic yes Hs578T myoepithel, fibroblast yes yes Estrogen dependent, hormone MCF-7 breast carcinoma yes yes yes pellets MCF-10A breast carcinoma no yes HER2 pos MDA -MB-231 breast adenocarcinoma, Pleural yes yes yes, also metastasis model +/- luc 2-3 6 for ortho 2 for subq for very attractive prices. Please contact us for details! Page 1 of 5 Last Updated: Mar 1, 2016

MDA-MB-361 breast carcinoma yes no HER2 pos MDA-MB-53 breast carcinoma yes yes HER2 pos MDA-MB-68 breast adenocarcinoma yes yes yes, also as metastasis model in slow growing 7 MMT 060562 Mouse breast carcinoma no yes SK-BR-3 breast carcinoma no yes HER2 pos T7D breast carcinoma not tumorigenic no Colon C170 adenocarcinoma, colorectal yes Colo-201 carcinoma, colorectal yes yes yes Colo-205 carcinoma, colorectal yes yes yes induction of cachexia 3- CT-26 Mouse carcinoma, colorectal yes no yes DLD-1 carcinoma, colorectal no yes 2 HCT-15 carcinoma, colorectal yes yes 2 HCT 116 carcinoma, colorectal yes yes yes 2- HT-29 adenocarcinoma, colorectal yes yes yes 2 Km12L carcinoma, colorectal no no LoVo carcinoma, colorectal yes no s.c. sensitive to 5FU 3- MC-38 Mouse adenocarinoma yes yes no C57BL/6 SW80 carcinoma, colorectal yes no SW620 carcinoma, colorectal yes no resistant WiDr carcinoma, colorectal yes no 2 Connective HT-1080 fibrosarcoma yes yes L-929 Mouse subcutaneous connective tissue; areolar and adipose not tumorigenic yes Sarcoma 180 Mouse sarcoma no yes Head & Neck SCC-15 squamous cell carcinoma no yes Kidney not tumorigenic, very slow growing 786-O renal cell adenocarcinoma yes yes not tested slow growing 3-5 ACHN renal cell adenocarcinoma yes yes not tested slow growing 3-5 Leukemia/Lymphoma - Bone Marrow RS()11 Acute lymphoblastic leukemia no yes SUP-B15 Acute lymphoblastic leukemia, B lymphoblast K-562 chronic myelogenous leukemia (CML) bone marrow yes yes 3- L-50 Hodgkin lymphoma no yes NCI-H929 Plasmacytoma, multiple myeloma (MM), B lymphocyte yes no in bone marrow of the tibia for very attractive prices. Please contact us for details! Page 2 of 5 Last Updated: Mar 1, 2016

Leukemia/Lymphoma - Peripheral Blood CCRF-CEM T lymphoblast, acute lymphoblastic leukemia no yes CEM/C1 T lymphoblast, acute lymphoblastic leukemia yes yes Daudi B lymphoblast, Burkitt's lymphoma (NHL) yes yes yes iv injection in SCID mice HD-MY-Z Hodgkin lymphoma no HL-60 Acute promyelocytic leukemia, promyeloblast yes yes from fragments KASUMI-1 Acute myeloblastic leukemia, myeloblast yes no L-1236 Hodgkin lymphoma no yes LP-1 Plasmacytoma, multiple myeloma yes no in bone marrow of the tibia MOLM-13 Acute myeloid leukemia no yes MOLT- Acute lymphoblastic leukemia, T lymphoblast no yes used in screening MUTZ-2 acute myeloid leukemia no yes used in screening MV()11 biphenotypic B myelomonocytic leukemia, macrophage yes yes yes i.v. injection in NOD SCID OCI-AML 2 Acute myeloid leukemia no yes used in screening PEER T cell acute lymphoblastic leukemia (T-ALL) no yes used in screening Raji Burkitt's lymphoma, B lymphocyte yes yes yes Ramos Burkitt s lymphoma, B lymphocyte yes no yes RPMI 8226 Plasmacytoma, multiple myeloma, B lymphocyte yes yes SKM-1 Acute myeloid leukemia no yes U937 Histiocytic lymphoma no yes Liver Hep 3B2.1-7 hepatocellular carcinoma yes yes yes HEPA 1-6 Mouse yes yes iv injection in SCID, also available as luc clone subcutaneous and orthotopic, >90% take rate HUH-7 carcinoma yes yes yes variable and fast growing, also available as luc2 3 PLC/PRF/5 hepatoma yes SK-HEP-1 adenocarcinoma yes yes yes SNU-182 hepatocellular carcinoma yes Lung A59 NSCLC yes yes 2 Calu-3 adenocarcinoma (Pleural effusion) yes no 3- Calu-6 H69AR HCC827 epithelial HOP-92 NSCLC, pleural effusion no yes 3- LL/2 Mouse Lewis Lung (C57BL6) yes no yes with LL-2 luc 2-3 3 for very attractive prices. Please contact us for details! Page 3 of 5 Last Updated: Mar 1, 2016

NCI-H69 SCLC, Small Cell Carcinoma yes yes from fragments 3- NCI-H82 NSCLC yes no 2- NCI-H16 NSCLC yes yes NCI-H209 SCLC, Small Cell Carcinoma yes yes high variability 3 NCI-H226 NSCLC yes yes NCI-H60 NSCLC, pleural effusion yes yes also with NCI-H60 luc 2 2- NCI-H520 NSCLC, Squamous cell carcinoma yes yes 2-3 NCI-H596 NSCLC, adenosquamous carcinoma yes yes from fragments -6 NCI-H1975 epithelial NCI-H1975 WI-38 normal fibroblast not tumorigenic yes Ovary A2780 ovary, adenocarcinoma yes 2-3 ADDP ovary, adenocarcinoma no no NCI ADR-res ovary, adenocarcinoma no yes NIH;OVCAR-3 ovary, adenocarcinoma yes yes SCID mice 5 NIH;OVCAR- ovary, adenocarcinoma no no NIH;OVCAR-5 ovary, adenocarcinoma no no SK-OV-3 adenocarcinoma, ovary, Malignant Ascites yes yes not tested SCID mice also available as SKOV3-luc-D3 Pancreas AsPC-1 adenocarcinoma no yes BxPC-3 adenocarcinoma yes yes 3-5 Capan-1 from liver mets no yes HupT L3.6pl carcinoma yes no metastasis in LN, pancectomy in preparation 2- MIA PaCa-2 carcinoma yes yes yes in Athymic Foxn1 nude 2- PANC-1 epithelioid carcinoma yes yes SCID mice 3-6 Pan02 Mouse carcinoma yes no C57Bl6 5 Prostate DU 15 prostate carcinoma yes yes slow growth rate LN-CaP prostate carcinoma yes yes Androgen depended -6 PC3 prostate adenocarcinoma yes yes inoculation into tibia tested (bone lysis model) also as 2-3 PC3 -luc prostate model PC3-M prostate adenocarcinoma yes yes metastasis, induction of cachexia 2-3 Skin A375 malignant melanoma yes yes 2-3 A31 B16-F0 Mouse melanoma yes in progress Yes, C57BL/6 (intradermal) 2 3-5 Pancreas for very attractive prices. Please contact us for details! Page of 5 Last Updated: Mar 1, 2016

B16-F10 Mouse melanoma yes yes Yes, C57BL/6 (intradermal) 2 C32 melanoma yes no s.c. 2 C8161 malignant melanoma yes no Yes, Athymic nude (intradermal) metastatic clone (lung) 3 CHL-1 melanoma yes no fast growing 2 G361 malignant melanoma yes yes HT 1 malignant melanoma yes Malme-3 malignant melanoma no yes Malme-3M malignant melanoma no yes lung and liver metastasis, induction of cachexia Orthotopic (intradermal) MDA-MB-35S melanoma not tumorigenic no not tested low take rate 3 SK-MEL-2 malignant melanoma no yes SK-MEL-5 malignant melanoma no yes SK-MEL-28 malignant melanoma no yes WM-266- melanoma, from metastatic site yes Stomach MKN-5 human, stomach, adenocarcinoma yes yes NCI-N87 gastric carcinoma no yes Testis F9 Mouse no yes Thyroid BHT-101 squamous cell carcinoma no yes 1-2 SW579 squamous cell carcinoma no yes Uterus MES-SA Uterine Sarcoma no yes MES-SA/Dx5 Uterine Sarcoma no yes Vulva SK-LMS-1 leiomysarcoma no no Other Hela cervical carcinoma no yes for very attractive prices. Please contact us for details! Page 5 of 5 Last Updated: Mar 1, 2016